American Journal of Hypertension最新文献

{"title":"Association between estimated daily salt intake from spot urine and nocturnal blood pressure in hypertensive patients under antihypertensive treatment.","authors":"Tatsuya Maruhashi, Yoshihiko Kinoshita, Ryoji Ozono, Mitsuaki Nakamaru, Masanori Ninomiya, Jiro Oiwa, Takuji Kawagoe, Osamu Yoshida, Toshiyuki Matsumoto, Yasuo Fukunaga, Kotaro Sumii, Hironori Ueda, Nobuo Shiode, Kosuke Takahari, Yasuhiko Hayashi, Yujiro Ono, Yukiko Nakano, Masakazu Takahashi, Yasuki Kihara, Yukihito Higashi","doi":"10.1093/ajh/hpaf095","DOIUrl":"https://doi.org/10.1093/ajh/hpaf095","url":null,"abstract":"<p><strong>Background: </strong>Excessive salt intake is a major contributor to hypertension and is associated with elevated nocturnal blood pressure (BP), particularly in the elderly and individuals with chronic kidney disease (CKD), metabolic syndrome (MetS), or diabetes, who are prone to nocturnal BP elevation in response to high salt intake. Although estimation of salt intake from spot urine is widely used, the relationship of estimated salt intake from spot urine with nighttime BP in treated patients with hypertension remains unclear.</p><p><strong>Methods: </strong>In this cross-sectional study, we analyzed 209 hypertensive patients receiving antihypertensive therapy. Estimated daily salt intake was calculated from spot urine using a validated formula. Nighttime BP was measured over a period of seven days using a home BP monitoring device.</p><p><strong>Results: </strong>The mean estimated salt intake was 9.3±2.5 g/day, and the mean nighttime systolic BP was 115.6±12.1 mmHg. There was no significant correlation between estimated salt intake and nighttime systolic BP (r=-0.08, P=0.23). Multivariable linear regression analysis also showed no significant association (β=-0.070, P=0.34). Subgroup analyses in participants aged ≥65 years and those with CKD, MetS, or diabetes showed no significant associations. Sensitivity analyses in participants with controlled morning BP (<135 mmHg) and those with a ≤7-day interval between spot urine and nighttime BP measurements also showed no significant associations.</p><p><strong>Conclusions: </strong>Estimated salt intake from spot urine was not significantly associated with nighttime systolic BP in treated hypertensive patients, even in those prone to salt-related nocturnal BP elevation.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stenotic Lesions of the Intracranial Arteries in Relation to the Average Level and Variability of the Home Blood Pressure: A Cross-Sectional Study.","authors":"Dong-Yan Zhang, De Wei An, Hui Chen, Jie Xu, Ying Wang, Yi-Bang Cheng, Qian-Hui Guo, Ming-Xuan Li, Qi-Fang Huang, Jian-Feng Huang, Chang-Sheng Sheng, Ji-Guang Wang, Jan A Staessen, Yan Li","doi":"10.1093/ajh/hpaf089","DOIUrl":"https://doi.org/10.1093/ajh/hpaf089","url":null,"abstract":"<p><strong>Background: </strong>This study assessed the presence of intracranial arterial stenosis (ICAS) in relation to home systolic blood pressure (SBP) and its variability (BPV).</p><p><strong>Methods: </strong>In 1510 untreated patients, ICAS was assessed by transcranial Doppler ultrasonography. SBP and BPV were determined from individual home BP recordings over seven days with triplicate readings in the morning and evening. BP variability was expressed as standard deviation (SD), coefficient of variation (CV), variability independent of the mean (VIM), and average real variability (ARV). CV was SD divided by the mean, VIM was SD divided by the mean to the power x and multiplied by the population mean to the power x, and ARV reflected the average absolute difference between consecutive BP readings. Associations with ICAS were assessed from nested multivariable logistic models.</p><p><strong>Results: </strong>114 participants (7.5%) had ICAS. Combining all BP readings, SBP, SD, CV, VIM, and ARV averaged (± between-patient SD) 130.1±11.9 mm Hg, 8.36±2.53 mm Hg, 6.42±1.83%, 8.36±2.38, and 6.41±1.61 mm Hg, respectively. In multivariable-adjusted models, higher home SBP were independently associated with increased prevalence of ICAS. For morning measurements, all variability indices were significantly associated with ICAS, with odds ratios per 1-SD increase ranging from 1.33 to 1.34 (P ≤ 0.005), independent of SBP level. In contrast, associations based on evening variability were non-significant. Sex and anatomical ICAS location did not impact on these results.</p><p><strong>Conclusions: </strong>The prevalence of ICAS was positively associated with SBP level. In addition to SBP level, all four morning BPV indexes refined assessment of ICAS prevalence.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arterial stiffness in children and adolescents with type 1 Diabetes mellitus or excess weight.","authors":"Eirini Kostopoulou, Marios Papasotiriou, Evangelos Papachristou, Dimitrios Goumenos, Konstantinos Miliordos, Dionysios Chrysis","doi":"10.1093/ajh/hpaf090","DOIUrl":"https://doi.org/10.1093/ajh/hpaf090","url":null,"abstract":"<p><strong>Background: </strong>The relationship between pediatric obesity or Type 1 Diabetes Mellitus (T1DM) and cardiovascular disease in adulthood is well established, with the pathophysiological mechanisms being already present in childhood. Arterial stiffness is a strong, independent predictor of cardiovascular disease in adulthood. In this study we evaluated arterial stiffness indices such as pulse wave velocity (PWV) and central blood pressure (cBP) in children and adolescents with T1DM or excess weight, in order to detect subclinical vascular alterations at a very early stage.</p><p><strong>Methods: </strong>A total of 199 children and adolescents aged 2-18 years participated in the study, including 96 with T1DM, 49 with overweight or obesity, and 54 healthy controls. PWV and cBP was measured using the automated oscillometric device Mobil-O-Graph.</p><p><strong>Results: </strong>Systolic BP (SBP) and central SBP (cSBP) were overall and especially in those >10 years of age, significantly higher in both patients with overweight/obesity and those with T1DM compared to controls. Furthermore, overweight/obesity patients had higher SBP, cSBP and cDBP compared to T1DM patients, whereas DBP was significantly higher only in overweight/obesity patients compared to controls. Pulse wave velocity values were also significantly higher in both overweight/obesity patients and those with T1DM compared to controls, while overweight/obesity patients had higher PWV when compared to patients with T1DM.</p><p><strong>Conclusions: </strong>Impaired arterial elasticity was found in children and adolescents older than 10 years, with T1DM and overweight/obesity, particularly in the latter. PWV could potentially serve as diagnostic tool for impaired vascular health in children and adolescents with T1DM or overweight/obesity.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in Adrenal Ablation for Primary Aldosteronism.","authors":"Isaac Glassman, Gregory L Hundemer","doi":"10.1093/ajh/hpaf091","DOIUrl":"https://doi.org/10.1093/ajh/hpaf091","url":null,"abstract":"","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to Recommended Laboratory Testing for Hypertension: Insights From A Nationwide Cohort.","authors":"Maximilian C Volk, Ahmad Safdar, Omer Ashruf, Luke J Laffin","doi":"10.1093/ajh/hpaf092","DOIUrl":"https://doi.org/10.1093/ajh/hpaf092","url":null,"abstract":"<p><strong>Background: </strong>Despite guideline recommendations, the prevalence of laboratory testing among patients newly diagnosed with hypertension (HTN) in the United States remains unknown. This study evaluated the prevalence of guideline-recommended laboratory testing in patients with newly diagnosed HTN.</p><p><strong>Methods: </strong>We conducted a retrospective analysis using the TriNetX database of adults ≥18 years newly diagnosed with HTN between 2018-2023. Patients were stratified by age, sex, race, and ethnicity. The primary outcome was prevalence of laboratory testing within six months of diagnosis, including complete blood count (CBC), basic/complete metabolic panel (BMP/CMP), lipid profile, thyroid-stimulating hormone (TSH), fasting glucose, urinalysis, and electrocardiogram (ECG).</p><p><strong>Results: </strong>Among 2,052,702 patients (mean age 59.3 years, 47.3% female), testing completion rates were: CBC (40.8%), BMP/CMP (42.7%), lipid profile (17.0%), TSH (14.8%), fasting glucose (9.6%), urinalysis (21.9%), and ECG (36.3%). Older age (≥65 years) was associated with higher completion rates for CBC (HR 1.19, 95% CI 1.19-1.20), BMP/CMP (HR 1.16, 95% CI 1.16-1.17), TSH (HR 1.14, 95% CI 1.13-1.15), fasting glucose (HR 1.34, 95% CI 1.32-1.35), urinalysis (HR 1.19, 95% CI 1.18-1.20), and ECG (HR 1.27, 95% CI 1.26-1.28). Female sex was associated with lower rates for CBC (HR 0.99, 95% CI 0.98-0.99), BMP/CMP (HR 0.96, 95% CI 0.95-0.96), lipid profile (HR 0.90, 95% CI 0.89-0.90), ECG (HR 0.96, 95% CI 0.96-0.97) but higher for TSH (HR 1.26, 95% CI 1.25-2.17) and urinalysis (HR 1.13, 95% CI 1.12-1.14).</p><p><strong>Conclusion: </strong>The prevalence of guideline-recommended laboratory testing among newly diagnosed HTN patients is low, with disparities across age, sex, race, and ethnicity.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients.","authors":"Eirik Olsen, Camilla L Søraas, Roland E Schmieder, Kenneth Jamerson, Thomas M MacDonald, Giuseppe Mancia, Sondre Heimark, Maria H Mehlum, Knut Liestöl, Anne C Larstorp, Julian E Mariampillai, Rune Mo, Lene V Halvorsen, Aud Høieggen, Morten Rostrup, Sverre E Kjeldsen, Michael A Weber","doi":"10.1093/ajh/hpaf093","DOIUrl":"https://doi.org/10.1093/ajh/hpaf093","url":null,"abstract":"<p><strong>Background: </strong>Protecting the kidneys by lowering systolic blood pressure (SBP) in hypertensive patients is not unequivocally settled. We tested the hypothesis that achieving lower average SBP in middle-aged and older high-risk hypertensive patients with and without type-2 diabetes mellitus through several years would clarify kidney protection.</p><p><strong>Methods: </strong>We analyzed patients 50-80 years with no cardiovascular events during the first 6 months of drug up-titration after randomization to valsartan or amlodipine, and with 3 or more visits onwards with standardized BP measurements. Adjusted Cox analyzes compared worsened kidney function defined as 50% rise in se-creatinine on a minimum of two occasions at least 4 weeks apart or end-stage kidney disease (ESKD) in achieved SBP quartiles and in patients who achieved SBP <130 and 130-139 mmHg with patients whose SBP remained >140 mmHg.</p><p><strong>Results: </strong>13,803 patients were investigated of whom 4,655 had DM. Patients with DM had less worsened kidney function at SBP 130-139 mmHg (HR=0.524, 95% CIs 0.375-0.733, n=1849, p<0.001) and at SBP <130 mmHg (HR=0.538, CIs 0.316-0.915, n=674, p=0.022) compared with patients at ≥140 mmHg. They also had less ESKD at SBP 130-139 mmHg (HR=0.442, CIs 0.196-1.000, p=0.050) with a similar trend at SBP <130 mmHg and in quartile analysis with only 1 ESKD in the lowest quartile. Findings in patients without DM (n=9,148) were similar to DM.</p><p><strong>Conclusions: </strong>In high-risk hypertensive patients of 50-80 years, with and without DM, targeting SBP of 130-139 mmHg confers kidney protection with possible further benefit at the lower target of SBP <130 mmHg.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of the COVID-19 epidemic on the association between antihypertensive drug interruption and the risk of major cardiovascular event in France.","authors":"Clément Mathieu, Julien Bezin, Antoine Pariente","doi":"10.1093/ajh/hpaf085","DOIUrl":"https://doi.org/10.1093/ajh/hpaf085","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic disrupted healthcare access, potentially impacting cardiovascular prevention by increasing and worsening interruptions in antihypertensive treatment. In this context, we aimed to assess whether the epidemic had modified the effect of antihypertensive interruptions on the risk of major cardiovascular events (MACE).</p><p><strong>Methods: </strong>From the nationwide SNDS French health insurance databases (2018/01/01-2021/12/31), we identified patients with ≥1 year of continuous antihypertensive drug use. We then constituted a group of patients who interrupted an antihypertensive during the period (interrupters) i.e. who presented with a treatment gap for at least one antihypertensive (entry date: interruption date). Interruption length defined was defined as time to treatment restart. After 1:1 matching, we constituted a second group of patients with continuous antihypertensive treatment at interrupters entry date (persisters; entry date: interrupter entry date). Associations between MACE risk, antihypertensive drug interruption (all durations, ≥15 days, ≥30 days), COVID epidemic period, and the interaction between these were assessed using GEE multivariable models.</p><p><strong>Results: </strong>A total of 2,072,672 interrupter/persister pairs were included (4,145,344 patients; 43.6% in COVID period). Risk of MACE was not found increased after interruptions overall (OR=0.99; 95%CI [0.97-1.02]); it was when interruptions lasted at least fifteen days (OR=1.03 [1.01-1.06]) and during the COVID period independently of the existence of interruptions (OR=1.44 [1.39-1.50]; p-value for interaction: all interruptions 0.69, exceeding 15 days 0.65).</p><p><strong>Conclusions: </strong>The COVID epidemic period was associated with an increased risk of MACE or all-cause death in antihypertensive drug users without worsening the effect of antihypertensive drug interruptions.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OGT-mediated O-GlcNAc of PINK1 promotes the progression of obesity-related hypertension via regulating mitophagy.","authors":"Xiaoling Zeng, Shengjiao Liang","doi":"10.1093/ajh/hpaf084","DOIUrl":"https://doi.org/10.1093/ajh/hpaf084","url":null,"abstract":"<p><strong>Background: </strong>Obesity causes a variety of metabolic diseases, including hypertension. O-linked beta-N-acetylglucosamine (O-GlcNAc), a dynamic post-translational modification, is rapidly cycled on and off proteins by O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), respectively. Our study hypothesized that O-GlcNAc contributes to the progression of obesity-related hypertension (OH). Using in vivo and in vitro approaches, we systematically investigated the role of O-GlcNAc in OH pathogenesis and elucidated its molecular mechanisms.</p><p><strong>Methods: </strong>An in vivo OH rat model was established through feeding with a high-fat diet. Besides, A7r5 cells were treated with oxidized low-density lipoprotein (ox-LDL) to simulate OH in vitro. Western blot was used to detect the protein levels of O-GlcNAc, OGT, OGA, and autophagy-related indicators. CCK-8 was performed to analyze the cell viability. The apoptosis rate was assessed by flow cytometry. Co-immunoprecipitation was performed to verify the endogenous interaction between OGT and PTEN-induced putative kinase (PINK)1.</p><p><strong>Results: </strong>OGT-mediated O-GlcNAc was elevated in both in vivo and in vitro OH models. Besides, OGT deficiency inhibited hypertension and inflammation, and increased autophagy in high-fat diet-induced OH rats. Additionally, OGT inhibition increased cell viability and autophagy and inhibited apoptosis in ox-LDL-treated A7r5 cells. Mechanically, OGT-mediated O-GlcNAc of PINK1 at S335 site regulated the phosphorylation of PINK1. Finally, PINK1 inhibition decreased cell viability and autophagy and promoted apoptosis in ox-LDL-treated A7r5 cells.</p><p><strong>Conclusion: </strong>OGT-mediated O-GlcNAc of PINK1 promoted the progression of OH via regulating mitophagy, which might provide a new insight for OH treatment.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma reactive dicarbonyls are not independently associated with arterial stiffness: The Maastricht Study.","authors":"Myrthe M van der Bruggen, Marleen M J van Greevenbroek, Bart Spronck, Coen D A Stehouwer, Tammo Delhaas, Koen D Reesink, Casper G Schalkwijk","doi":"10.1093/ajh/hpaf068","DOIUrl":"https://doi.org/10.1093/ajh/hpaf068","url":null,"abstract":"<p><strong>Background: </strong>Arterial stiffness is a strong predictor of cardiovascular diseases and all-cause mortality. Increased concentrations of highly reactive dicarbonyl compounds - methylglyoxal (MGO), glyoxal (GO), and/or 3-deoxyglucosone (3-DG) - may cause arterial stiffening via formation of advanced glycation end products, triggering maladaptive responses in vascular tissue, e.g., elastin degradation and collagen cross-linking. Therefore, we investigated in the population-based Maastricht study whether plasma MGO, GO, and 3-DG concentrations were cross-sectionally associated with carotid-to-femoral pulse wave velocity (cfPWV) and local carotid stiffness measures: pulse wave velocity (cPWV), and Young's elastic modulus (cYEM) using standardized main variables.</p><p><strong>Methods: </strong>Fasting dicarbonyl concentrations were determined by ultra-performance liquid chromatography tandem mass spectrometry in EDTA plasma collected from 2275 participants (age 60±8 years, mean±SD; 49% women, 605 (27%) with type 2 diabetes mellitus) of the Maastricht Study, an observational, population-based cohort study. Cross-sectional associations were assessed using multivariable linear regression analysis adjusting for age, sex, mean arterial pressure (MAP), heart rate, lifestyle factors, and medication. Since arterial stiffness measures are intrinsically pressure dependent, we additionally assessed the associations with pressure-corrected counterparts, instead of statistically correcting for MAP.</p><p><strong>Results: </strong>Fasting dicarbonyl concentrations were associated with arterial stiffness measures (greater cfPWV, cPWV and cYEM) in most crude models, but not in adjusted models. The use of pressure-corrected metrics did not materially change the association of interest.</p><p><strong>Conclusion: </strong>Fasting plasma concentrations of either MGO, GO, or 3-DG are not independently associated with arterial stiffness in this cross-sectional analysis.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Transcriptomic and Metabolomic Analysis of Rat PASMCs Reveals the Underlying Mechanism for Pulmonary Arterial Hypertension.","authors":"Jie Hou, Ke Liu, Meng-Jie Zhang, Xiao-He Xu, Fang-Fang Meng, Chen-Chen Wang, Ou Yang, Lu-Ling Zhao, Meng-Wei Wang, Yun-Feng Zhou, Xiao-Bin Pang, Yang-Yang He, Jie-Jian Kou, Xin-Mei Xie, Hong-Da Zhang, Jun-Zhuo Shi","doi":"10.1093/ajh/hpaf015","DOIUrl":"10.1093/ajh/hpaf015","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary arterial hypertension (PAH) is a kind of pulmonary vascular lesion characterized by vasoconstriction and reshaping of small pulmonary arteries, ultimately resulting in increased pulmonary artery pressure and pulmonary vascular resistance, and eventually leading to right ventricular failure and death. This study was aimed to construct a platelet-derived growth factor BB (PDGF-BB)-induced rat pulmonary artery smooth muscle cells (PASMCs) model and conduct a combined transcriptomic and metabolomic analysis to identify proliferation-related targets, thereby enhancing the understanding of the pathogenesis underlying PAH.</p><p><strong>Methods: </strong>Rat PASMCs were isolated and cultured in the presence or absence of PDGF-BB for 24 hours. Cells were collected for transcriptomics and metabolomics investigations.</p><p><strong>Results: </strong>A total of 1,288 differentially expressed genes (DEGs; 572 upregulated and 716 downregulated) were identified in PDGF-BB-treated rat PASMCs compared with control cells. Subsequently, Gene ontology (GO) enrichment analysis revealed that 791 enriched GO terms were significantly enriched in PDGF-BB treated cells. Similarly, 294 differential metabolic pathways were enriched in PDGF-BB-treated cells according to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and Gene Set Enrichment Analysis was performed on the DEGs. It turned out that 7,219 gene sets were more enriched in PDGF-BB treated cells. In addition, a total of 28 secondary differential metabolites were identified in PDGF-BB-treated rat PASMCs compared with control cells (P-value < 0.05 and VIP > 1).</p><p><strong>Conclusions: </strong>We speculate that Mylk, Pla2g4a, Gucy1b1, Adcy8, Adcy4, Gucy1a2, Col3a1, and Plcb4 are potential targets for the treatment of PAH.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"398-408"},"PeriodicalIF":3.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143121711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}